INIBIBB   05455
INSTITUTO DE INVESTIGACIONES BIOQUIMICAS DE BAHIA BLANCA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Effects of terpenoids on C. elegans neuromuscular transmission
Autor/es:
TURANI, O.; HERNANDO G; BOUZAT, C.
Lugar:
Buenos Aires
Reunión:
Congreso; 2nd Congress of the Federation of Latin-American and Caribbean Societies for Neuroscience (FALAN); 2016
Institución organizadora:
SAN-FALAN
Resumen:
Effects of terpenoids on C. elegans neuromuscular transmissionTurani Ornella, Hernando Guillermina and Bouzat CeciliaInstituto de Investigaciones Bioquímicas de Bahía Blanca, UNS-CONICET, Bahía Blanca, Argentina.The free-living nematode Caenorhabditis elegans is a model organism to study the nervous system. Nematode muscle Cys-loop receptors mediate rapid synaptic transmission and are involved in neuromuscular transmission and worm locomotion. In parasites, they are clinically important because they are targets of anthelmintic drugs. We use C. elegans to identify novel anthelmintic agents and the target receptors. We found that three terpenoids, thymol, carvacrol, and eugenol, impair locomotion of wild-type C. elegans. The three compounds (< 2 mM) paralyze adult and larval worms in less than 2 h, indicating a rapid action compatible with the involvement of ligand-gated ion channels. The type of paralysis induced by all compounds is neither flaccid, as that induced by GABA activation, nor spastic, as that induced by activation of nicotinic receptors (nAChRs). To gain further insights into the potential drug targets we tested their effects on null mutants of Cys-loop receptors involved in locomotion. We found that glutamate receptors are not involved in the effect. In contrast, worms lacking UNC-49 (GABA) receptors or Levamisole-sensitive nAChRs are partially resistant to these compounds. Thus, these two receptors are the targets of the terpenoids. Their dual action explains the observed intermediate phenotypes. The discovery of novel paralyzing compounds and their receptor targets in C. elegans contributes to the development of anthelmintic therapies.